Triple–Hormone-Receptor Agonist Retatrutide for Obesity — A Phase 2 Trial
Triple–Hormone-Receptor Agonist Retatrutide for Obesity — A Phase 2 Trial is a paper indexed in ScholarIQ from OpenAlex.
How many citations does Triple–Hormone-Receptor Agonist Retatrutide for Obesity — A Phase 2 Trial have?
Triple–Hormone-Receptor Agonist Retatrutide for Obesity — A Phase 2 Trial has 1,028 citations in the OpenAlex counts ScholarIQ stores.
When was Triple–Hormone-Receptor Agonist Retatrutide for Obesity — A Phase 2 Trial published?
Triple–Hormone-Receptor Agonist Retatrutide for Obesity — A Phase 2 Trial has 2023 year in the ScholarIQ index.
What is the open-access status of Triple–Hormone-Receptor Agonist Retatrutide for Obesity — A Phase 2 Trial?
Triple–Hormone-Receptor Agonist Retatrutide for Obesity — A Phase 2 Trial has closed oa status in the ScholarIQ index.
What is the DOI of Triple–Hormone-Receptor Agonist Retatrutide for Obesity — A Phase 2 Trial?
The DOI for Triple–Hormone-Receptor Agonist Retatrutide for Obesity — A Phase 2 Trial is on the source record.
What is the PMID of Triple–Hormone-Receptor Agonist Retatrutide for Obesity — A Phase 2 Trial?
The PMID for Triple–Hormone-Receptor Agonist Retatrutide for Obesity — A Phase 2 Trial is on the source record.
What is the OpenAlex record for Triple–Hormone-Receptor Agonist Retatrutide for Obesity — A Phase 2 Trial?
The OpenAlex for Triple–Hormone-Receptor Agonist Retatrutide for Obesity — A Phase 2 Trial is on the source record.